Atopaxar and its effects on markers of platelet activation and inflammation: results from the LANCELOT CAD program

Vorapaxar in the Secondary Prevention of Atherothrombotic Events

(2012) David A. Morrow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Randomized Trial of Atopaxar in the Treatment of Patients With Coronary Artery Disease

(2011) Stephen D. Wiviott et al.   CIRCULATION

Safety and Tolerability of Atopaxar in the Treatment of Patients With Acute Coronary Syndromes

(2011) Michelle L. O'Donoghue et al.   CIRCULATION

Changes in Inflammatory Biomarkers in Patients Treated With Ticagrelor or Clopidogrel

(2010) Steen Husted et al.   CLINICAL CARDIOLOGY

Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease

(2010) S. Goto et al.   EUROPEAN HEART JOURNAL

Platelet thrombin receptor antagonism and atherothrombosis

(2009) D. J. Angiolillo et al.   EUROPEAN HEART JOURNAL